A role for versican in the development of leiomyosarcoma

Journal of Biological Chemistry

Volumn 289, Issue 49, 2014, Pages 34089-34103

  Keire, Paul A ^a,b   Bressler, Steven L ^a   Lemire, Joan M ^b,f   Edris, Badreddin ^c   Rubin, Brian P ^b,g   Rahmani, Maziar ^d,e,h   McManus, Bruce M ^d,e   Van De Rijn, Matt ^c   Wight, Thomas N ^a,b  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ST PAUL S HOSPITAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f TUFTS UNIVERSITY   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION; CELL CULTURE; CELL PROLIFERATION; HYALURONIC ACID; TUMORS;

DOSE-DEPENDENT MANNER; EXTRACELLULAR MATRICES; HUMAN CELL LINES; LEIOMYOSARCOMA; MICROARRAY ANALYSIS; PROTEOGLYCANS; SMOOTH MUSCLE CELLS; SYNTHASE EXPRESSION;

CELLS;

HYALURONIC ACID; SMALL INTERFERING RNA; VERSICAN; GLUCURONOSYLTRANSFERASE; HYALURONAN SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEIOMYOSARCOMA; MICROARRAY ANALYSIS; MITOSIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUSCLE TUMOR; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; TISSUE MICROARRAY; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HUMANS; HYALURONIC ACID; LEIOMYOSARCOMA; MICE; MICE, NUDE; MUSCLE NEOPLASMS; MUSCLE, SMOOTH; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; VERSICANS;

EID: 84917706090     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.607168     Document Type: Article

References (79)

1. Major, F. J., Blessing, J. A., Silverberg, S. G., Morrow, C. P., Creasman, W. T., Currie, J. L., Yordan, E., and Brady, M. F. (1993) Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71, 1702-1709
2. Moinfar, F., Azodi, M., and Tavassoli, F. A. (2007) Uterine sarcomas. Pathology 39, 55-71
3. Zako, M., Shinomura, T., Ujita, M., Ito, K., and Kimata, K. (1995) Expression of PG-M (V3), an alternatively spliced form of PG-M without a chondroitin sulfate attachment region in mouse and human tissues. J. Biol. Chem. 270, 3914-3918
4. Wight, T. N., Kinsella, M. G., Evanko, S. P., Potter-Perigo, S., and Merrilees, M. J. (2014) Versican and the regulation of cell phenotype in disease. Biochim. Biophys. Acta 1840, 2441-2451
5. Lemire, J. M., Braun, K. R., Maurel, P., Kaplan, E. D., Schwartz, S. M., and Wight, T. N. (1999) Versican/PG-M isoforms in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 19, 1630-1639
6. Du, W. W., Yang, W., and Yee, A. J. (2013) Roles of versican in cancer biology-tumorigenesis, progression and metastasis. Histol. Histopathol. 28, 701-713
7. Wu, Y. J., La Pierre, D. P., Wu, J., Yee, A. J., and Yang, B. B. (2005) The interaction of versican with its binding partners. Cell Res. 15, 483-494
8. Bode-Lesniewska, B., Dours-Zimmermann, M. T., Odermatt, B. F., Briner, J., Heitz, P. U., and Zimmermann, D. R. (1996) Distribution of the large aggregating proteoglycan versican in adult human tissues. J. Histochem. Cytochem. 44, 303-312
9. Theocharis, A. D., Skandalis, S. S., Tzanakakis, G. N., and Karamanos, N. K. (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 277, 3904-3923
10. Wight, T. N., Kang, I., and Merrilees, M. J. (2014) Versican and the control of inflammation. Matrix Biol. 35, 152-161
11. Ricciardelli, C., Sakko, A. J., Ween, M. P., Russell, D. L., and Horsfall, D. J. (2009) The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev. 28, 233-245
12. Sakko, A. J., Ricciardelli, C., Mayne, K., Suwiwat, S., LeBaron, R. G., Marshall, V. R., Tilley, W. D., and Horsfall, D. J. (2003) Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res. 63, 4786-4791
13. Kim, S., Takahashi, H., Lin, W. W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J. L., and Karin, M. (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102-106
14. Labropoulou, V. T., Theocharis, A. D., Ravazoula, P., Perimenis, P., Hjerpe, A., Karamanos, N. K., and Kalofonos, H. P. (2006) Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumours. Histopathology 49, 582-593
15. Nikitovic, D., Zafiropoulos, A., Katonis, P., Tsatsakis, A., Theocharis, A. D., Karamanos, N. K., and Tzanakakis, G. N. (2006) Transforming growth factor-β as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 58, 47-53
16. Gao, D., Vahdat, L. T., Wong, S., Chang, J. C., and Mittal, V. (2012) Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 72, 4883-4889
17. Said, N., Sanchez-Carbayo, M., Smith, S. C., and Theodorescu, D. (2012) RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J. Clin. Investig. 122, 1503-1518
18. Arslan, A. A., Gold, L. I., Mittal, K., Suen, T. C., Belitskaya-Levy, I., Tang, M. S., and Toniolo, P. (2005) Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum. Reprod. 20, 852-863
19. Sobue, M., Takeuchi, J., Yoshida, K., Akao, S., Fukatsu, T., Nagasaka, T., and Nakashima, N. (1987) Isolation and characterization of proteoglycans from human nonepithelial tumors. Cancer Res. 47, 160-168
20. Cattaruzza, S., Schiappacassi, M., Kimata, K., Colombatti, A., and Perris, R. (2004) The globular domains of PG-M/versican modulate the proliferation- apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J. 18, 779-781
21. Fletcher, C., Unni, K., and Mertens, F. (eds) (2002) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone, III Ed., Vol. 4, pp. 130-134, IARC Press, Lyon, France
22. Guillou, L., Coindre, J. M., Bonichon, F., Nguyen, B. B., Terrier, P., Collin, F., Vilain, M. O., Mandard, A. M., Le Doussal, V., Leroux, A., Jacquemier, J., Duplay, H., Sastre-Garau, X., and Costa, J. (1997) Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J. Clin. Oncol. 15, 350-362
23. du Cros, D. L., LeBaron, R. G., and Couchman, J. R. (1995) Association of versican with dermal matrices and its potential role in hair follicle development and cycling. J. Invest. Dermatol. 105, 426-431
24. Chomczynski, P. (1993) A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. BioTechniques 15, 532-534, 536-537
25. Schönherr, E., Kinsella, M. G., and Wight, T. N. (1997) Genistein selectively inhibits platelet-derived growth factor stimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch. Biochem. Biophys. 339, 353-361
26. Beck, A. H., Lee, C. H., Witten, D. M., Gleason, B. C., Edris, B., Espinosa, I., Zhu, S., Li, R., Montgomery, K. D., Marinelli, R. J., Tibshirani, R., Hastie, T., Jablons, D. M., Rubin, B. P., Fletcher, C. D., West, R. B., and van de Rijn, M. (2010) Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene 29, 845-854
27. Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., Lønning, P. E., Børresen- Dale, A. L., Brown, P. O., and Botstein, D. (2000) Molecular portraits of human breast tumours. Nature 406, 747-752
28. Eskander, R. N., Randall, L. M., Sakai, T., Guo, Y., Hoang, B., and Zi, X. (2012) Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. J. Obstet. Gynaecol. Res. 38, 1086-1094
29. Yang, J., Eddy, J. A., Pan, Y., Hategan, A., Tabus, I., Wang, Y., Cogdell, D., Price, N. D., Pollock, R. E., Lazar, A. J., Hunt, K. K., Trent, J. C., and Zhang, W. (2010) Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug. Mol. Cell. Proteomics 9, 2405-2413
30. Gao, C. F., Xie, Q., Zhang, Y. W., Su, Y., Zhao, P., Cao, B., Furge, K., Sun, J., Rex, K., Osgood, T., Coxon, A., Burgess, T. L., and Vande Woude, G. F. (2009) Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Mol. Cancer Ther. 8, 2803-2810
31. Horiuchi, A., Nikaido, T., Mitsushita, J., Toki, T., Konishi, I., and Fujii, S. (2000) Enhancement of antitumor effect of bleomycin by low-voltage in vivo electroporation: a study of human uterine leiomyosarcomas in nude mice. Int. J. Cancer 88, 640-644
32. Myslinski, E., Amé, J. C., Krol, A., and Carbon, P. (2001) An unusually compact external promoter for RNA polymerase III transcription of the human H1RNA gene. Nucleic Acids Res. 29, 2502-2509
33. Fogh, J., and Trempe, G. (1975) in Human Tumor Cells in Vitro (Fogh, J., ed) pp. 115-159, Plenum Press, New York
34. Schönherr, E., Järveläinen, H. T., Sandell, L. J., and Wight, T. N. (1991) Effects of platelet-derived growth factor and transforming growth factor-β1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J. Biol. Chem. 266, 17640-17647
35. Hascall, V. C., Calabro, A., Midura, R. J., and Yanagishita, M. (1994) Isolation and characterization of proteoglycans. Methods Enzymol. 230, 390-417
36. Olin, K. L., Potter-Perigo, S., Barrett, P. H., Wight, T. N., and Chait, A. (1999) Lipoprotein lipase enhances the binding of native and oxidized low density lipoproteins to versican and biglycan synthesized by cultured arterial smooth muscle cells. J. Biol. Chem. 274, 34629-34636
37. Yu, Q., and Toole, B. P. (1995) Biotinylated hyaluronan as a probe for detection of binding proteins in cells and tissues. BioTechniques 19, 122-124, 126-129
38. Underhill, C. B., Nguyen, H. A., Shizari, M., and Culty, M. (1993) CD44 positive macrophages take up hyaluronan during lung development. Dev. Biol. 155, 324-336
39. Wilkinson, T. S., Potter-Perigo, S., Tsoi, C., Altman, L. C., and Wight, T. N. (2004) Pro- and anti-inflammatory factors cooperate to control hyaluronan synthesis in lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 31, 92-99
40. Evanko, S. P., Johnson, P. Y., Braun, K. R., Underhill, C. B., Dudhia, J., and Wight, T. N. (2001) Platelet-derived growth factor stimulates the formation of versican-hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells. Arch. Biochem. Biophys. 394, 29-38
41. Hyacinthe, M., Jaroszeski, M. J., Dang, V. V., Coppola, D., Karl, R. C., Gilbert, R. A., and Heller, R. (1999) Electrically enhanced drug delivery for the treatment of soft tissue sarcoma. Cancer 85, 409-417
42. Evanko, S. P., Tammi, M. I., Tammi, R. H., and Wight, T. N. (2007) Hyaluronan-dependent pericellular matrix. Adv. Drug Deliv. Rev. 59, 1351-1365
43. Cattaruzza, S., and Perris, R. (2005) Proteoglycan control of cell movement during wound healing and cancer spreading. Matrix Biol. 24, 400-417
44. Kodama, J., Hasengao, WA., Kusumoto, T., Seki, N., Matsuo, T., Nakamura, K., Hongo, A., and Hiramatsu, Y. (2007) Versican expression in human cervical cancer. Eur. J. Cancer 43, 1460-1466
45. Skandalis, S. S., Theocharis, A. D., Papageorgakopoulou, N., Vynios, D. H., and Theocharis, D. A. (2006) The increased accumulation of structurally modified versican and decorin is related with the progression of laryngeal cancer. Biochimie 88, 1135-1143
46. Theocharis, A. D., Vynios, D. H., Papageorgakopoulou, N., Skandalis, S. S., and Theocharis, D. A. (2003) Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int. J. Biochem. Cell Biol. 35, 376-390
47. Mäkinen, N., Mehine, M., Tolvanen, J., Kaasinen, E., Li, Y., Lehtonen, H. J., Gentile, M., Yan, J., Enge, M., Taipale, M., Aavikko, M., Katainen, R., Virolainen, E., Böhling, T., Koski, T. A., Launonen, V., Sjöberg, J., Taipale, J., Vahteristo, P., and Aaltonen, L. A. (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334, 252-255
48. Rahmani, M., Wong, B. W., Ang, L., Cheung, C. C., Carthy, J. M., Walinski, H., and McManus, B. M. (2006) Versican: signaling to transcriptional control pathways. Can. J. Physiol. Pharmacol. 84, 77-92
49. Weiss, S., and Goldblum, J. (2001) Enzinger and Weiss's Soft Tissue Tumors, 4th Ed., pp. 695-748, Mosby, St. Louis, MO
50. Ranchod, M., and Kempson, R. L. (1977) Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: a pathologic analysis of 100 cases. Cancer 39, 255-262
51. Shmookler, B. M., and Lauer, D. H. (1983) Retroperitoneal leiomyosarcoma. A clinicopathologic analysis of 36 cases. Am. J. Surg. Pathol. 7, 269-280
52. Perrone, T., and Dehner, L. P. (1988) Prognostically favorable "mitotically active" smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases. Am. J. Surg. Pathol. 12, 1-8
53. Jones, M. W., and Norris, H. J. (1995) Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis. Int. J. Gynecol. Pathol. 14, 243-249
54. Robboy, S. J., Bentley, R. C., Butnor, K., and Anderson, M. C. (2000) Pathology and pathophysiology of uterine smooth-muscle tumors. Environ. Health Perspect. 108, Suppl. 5, 779-784
55. Yamagata, M., and Kimata, K. (1994) Repression of a malignant cell-substratum adhesion phenotype by inhibiting the production of the antiadhesive proteoglycan, PG-M/versican. J. Cell Sci. 107, 2581-2590
56. Yamagata, M., Saga, S., Kato, M., Bernfield, M., and Kimata, K. (1993) Selective distributions of proteoglycans and their ligands in pericellular matrix of cultured fibroblasts. Implications for their roles in cell-substratum adhesion. J. Cell Sci. 106, 55-65
57. Bu, P., and Yang, P. (2014) MicroRNA-203 inhibits malignant melanoma cell migration by targeting versican. Exp. Ther. Med. 8, 309-315
58. Hernández, D., Miquel-Serra, L., Docampo, M. J., Marco-Ramell, A., and Bassols, A. (2011) Role of versican V0/V1 and CD44 in the regulation of human melanoma cell behavior. Int. J. Mol. Med. 27, 269-275
59. Li, D., Wang, X., Wu, J. L., Quan, W. Q., Ma, L., Yang, F., Wu, K. Y., and Wan, H. Y. (2013) Tumor-produced versican V1 enhances hCAP18/LL-37 expression in macrophages through activation of TLR2 and vitamin D3 signaling to promote ovarian cancer progression in vitro. PLoS One 8, e56616
60. Bögels, M., Braster, R., Nijland, P. G., Gül, N., van de Luijtgaarden, W., Fijneman, R. J., Meijer, G. A., Jimenez, C. R., Beelen, R. H., and van Egmond, M. (2012) Carcinoma origin dictates differential skewing of monocyte function. Oncoimmunology 1, 798-809
61. Li, F., Ten Dam, G. B., Murugan, S., Yamada, S., Hashiguchi, T., Mizumoto, S., Oguri, K., Okayama, M., van Kuppevelt, T. H., and Sugahara, K. (2008) Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells. J. Biol. Chem. 283, 34294-34304
62. Ra, H. J., Harju-Baker, S., Zhang, F., Linhardt, R. J., Wilson, C. L., and Parks, W. C. (2009) Control of promatrilysin (MMP7) activation and substratespecific activity by sulfated glycosaminoglycans. J. Biol. Chem. 284, 27924-27932
63. Yeung, T. L., Leung, C. S., Wong, K. K., Samimi, G., Thompson, M. S., Liu, J., Zaid, T. M., Ghosh, S., Birrer, M. J., and Mok, S. C. (2013) TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 73, 5016-5028
64. Koyama, H., Hibi, T., Isogai, Z., Yoneda, M., Fujimori, M., Amano, J., Kawakubo, M., Kannagi, R., Kimata, K., Taniguchi, S., and Itano, N. (2007) Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am. J. Pathol. 170, 1086-1099
65. Toole, B. P. (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 4, 528-539
66. Kosaki, R., Watanabe, K., and Yamaguchi, Y. (1999) Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage- independent growth and tumorigenicity. Cancer Res. 59, 1141-1145
67. Li, Y., and Heldin, P. (2001) Hyaluronan production increases the malignant properties of mesothelioma cells. Br. J. Cancer 85, 600-607
68. Liu, N., Gao, F., Han, Z., Xu, X., Underhill, C. B., and Zhang, L. (2001) Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res. 61, 5207-5214
69. Tofuku, K., Yokouchi, M., Murayama, T., Minami, S., and Komiya, S. (2006) HAS3-related hyaluronan enhances biological activities necessary for metastasis of osteosarcoma cells. Int. J. Oncol. 29, 175-183
70. Ricciardelli, C., Russell, D. L., Ween, M. P., Mayne, K., Suwiwat, S., Byers, S., Marshall, V. R., Tilley, W. D., and Horsfall, D. J. (2007) Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J. Biol. Chem. 282, 10814-10825
71. Mitropoulou, T. N., Theocharis, A. D., Stagiannis, K. D., and Karamanos, N. K. (2001) Identification, quantification and fine structural characterization of glycosaminoglycans from uterine leiomyoma and normal myometrium. Biochimie 83, 529-536
72. Zheng, P. S., Wen, J., Ang, L. C., Sheng, W., Viloria-Petit, A., Wang, Y., Wu, Y., Kerbel, R. S., and Yang, B. B. (2004) Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J. 18, 754-756
73. Sheng, W., Wang, G., Wang, Y., Liang, J., Wen, J., Zheng, P. S., Wu, Y., Lee, V., Slingerland, J., Dumont, D., and Yang, B. B. (2005) The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol. Biol. Cell 16, 1330-1340
74. Hamilton, S. R., Fard, S. F., Paiwand, F. F., Tolg, C., Veiseh, M., Wang, C., McCarthy, J. B., Bissell, M. J., Koropatnick, J., and Turley, E. A. (2007) The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J. Biol. Chem. 282, 16667-16680
75. Havre, P. A., Dang, L. H., Ohnuma, K., Iwata, S., Morimoto, C., and Dang, N. H. (2013) CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of versican and MT1-MMP and enhanced adhesion. BMC Cancer 13, 517
76. Subramaniam, V., Vincent, I. R., Gardner, H., Chan, E., Dhamko, H., and Jothy, S. (2007) CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation. Exp. Mol. Pathol. 83, 207-215
77. Kastner, S., Thomas, G. J., Jenkins, R. H., Davies, M., and Steadman, R. (2007) Hyaluronan induces the selective accumulation of matrix- and cellassociated proteoglycans by mesangial cells. Am. J. Pathol. 171, 1811-1821
78. Evanko, S. P., Angello, J. C., and Wight, T. N. (1999) Formation of hyaluronan-and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 19, 1004-1013
79. Lemire, J. M., Chan, C. K., Bressler, S., Miller, J., LeBaron, R. G., and Wight, T. N. (2007) Interleukin-1β selectively decreases the synthesis of versican by arterial smooth muscle cells. J. Cell. Biochem. 101, 753-766